SGLT

Quick View
Dapagliflozin (BMS512148)

Catalog No. A10285
Quick View

Add to Wishlist
SGLT2 inhibitor

Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Learn More

Product Citations (5)

Bulk Inquiry Free Sample
- David Papadopoli, .et al. Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin, Neoplasia, 2021, Apr;23(4):391-399 PMID: 33784591
- Neil Tanday, .et al. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance, Biochem Pharmacol, 2020, Jul;177:114009 PMID: 32360307
- Subramaniam M, .et al. Comparison of Intestinal Glucose Flux and Electrogenic Current Demonstrates Two Absorptive Pathways in Pig and One in Nile Tilapia and Rainbow Trout, Am J Physiol Regul Integr Comp Physiol, 2019, Nov 20 PMID: 31746628
- Marina Subramaniam, .et al. Sigmoidal kinetics define porcine intestinal segregation of electrogenic monosaccharide transport systems as having multiple transporter population involvement, Physiol Rep, 2019, May; 7(9): e14090 PMID: 31062524
- Angelopoulou A, .et al. Magnetic Nanoparticles for the Delivery of Dapagliflozin to Hypoxic Tumors: Physicochemical Characterization and Cell Studies, AAPS PharmSciTech, 2018, Feb;19(2):621-633 PMID: 8924948
Quick View
Canagliflozin

Catalog No. A11100
Quick View

Add to Wishlist
SGLT2 Inhibitor

Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2). Learn More

Product Citations (2)

Bulk Inquiry Free Sample
- David Papadopoli, .et al. Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin, Neoplasia, 2021, Apr;23(4):391-399 PMID: 33784591
- Angelopoulou A, .et al. Canagliflozin-loaded magnetic nanoparticles as potential treatment of hypoxic tumors in combination with radiotherapy, Nanomedicine, 2018, Oct;13(19):2435-2454 PMID: 30311542
Quick View
EGT1442

Catalog No. A10155
Quick View

Add to Wishlist
SGLT2 inhibitor

EGT1442 is a potent and selective SGLT2 inhibitor. Learn More

Bulk Inquiry
Quick View
Empagliflozin

Catalog No. A12440
Quick View

Add to Wishlist
Empagliflozin is a potent, selective sodium glucose co-transporter-2 inhibitor that is in development for the treatment of type 2 diabetes. Learn More

Product Citations (3)

Bulk Inquiry Free Sample
- Yu-Jung Heo, .et al. Empagliflozin Reduces the Progression of Hepatic Fibrosis in a Mouse Model and Inhibits the Activation of Hepatic Stellate Cells via the Hippo Signalling Pathway, Biomedicines, 2022, Apr 29;10(5):1032 PMID: 35625768
- Nami Lee, .et al. Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF- κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways, J Immunol Res, 2021, Jun 2;2021:9944880 PMID: 34124273
- CN Koyani, .et al. Empagliflozin Protects Heart From Inflammation and Energy Depletion via AMPK Activation, Pharmacol Res, 2020, May 17;158:104870 PMID: 32434052
Quick View
LX-4211

Catalog No. A12680
Quick View

Add to Wishlist
SGLT Inhibitor‎

LX4211 is a Dual SGLT1/SGLT2 Inhibitor Learn More

Bulk Inquiry Free Sample
Quick View
Tofogliflozin

Catalog No. A12690
Quick View

Add to Wishlist
SGLT2 inhibitor

Tofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Learn More

Bulk Inquiry
Quick View
Remogliflozin

Catalog No. A13971
Quick View

Add to Wishlist
SGLT2 inhibitor

Remogliflozin inhibits the sodium-glucose transport (SGLT2) proteins, which are responsible for glucose reabsorption in the kidney. Learn More

Bulk Inquiry
Quick View
Ipragliflozin

Catalog No. A13556
Quick View

Add to Wishlist
SGLT2 inhibitor

Ipragliflozin is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6. Learn More

Bulk Inquiry
Quick View
Luseogliflozin

Catalog No. A13476
Quick View

Add to Wishlist
SGLT2 Inhibitor

Luseogliflozin is an orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Taisho Pharmaceutical for the treatment of patients with type 2 diabetes mellitus (T2DM). Learn More

Bulk Inquiry
Quick View
T-1095

Catalog No. A15463
Quick View

Add to Wishlist
Na+-glucose transporter inhibitor

T-1095 is a potent and selective inhibitor of Na+-glucose cotransporters (SGLTs). Learn More

Bulk Inquiry Free Sample
Quick View
Canagliflozin hemihydrate

Catalog No. A16817
Quick View

Add to Wishlist
SGLT2 inhibitor

Canagliflozin hemihydrate is the hemihydrate form of canagliflozin, which is a SGLT2 inhibitor with IC50 of 2.2 nM for hSGLT2 in a cell-free assay, exhibits 413-fold selectivity over hSGLT1. Learn More

Bulk Inquiry
Quick View
Ertugliflozin L-pyroglutamic acid

Catalog No. A18054
Quick View

Add to Wishlist
SGLT inhibitor

Ertugliflozin pidolate belongs to the class of potent and selective inhibitors of the sodium-dependent glucose cotransporters (SGLT), more specifically the type 2 which is responsible for about 90% of the glucose reabsorption from glomerulus. Learn More

Bulk Inquiry
Quick View
SGL5213

Catalog No. A18723
Quick View

Add to Wishlist
SGLT1 inhibitor

SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. Learn More

Bulk Inquiry
Quick View
Dapagliflozin impurity

Catalog No. A19103
Quick View

Add to Wishlist
SGLT2 inhibitor

Dapagliflozin impurity is an enantiomer of Dapagliflozin which is a sodium-glucose transporter 2 inhibitor. Learn More

Bulk Inquiry
Quick View
Licogliflozin

Catalog No. A12828
Quick View

Add to Wishlist
SGLT1/SGLT2 inhibitor

Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor. Learn More

Bulk Inquiry